NASDAQ:ANEB Anebulo Pharmaceuticals (ANEB) Stock Forecast, Price & News $3.06 +0.03 (+0.99%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$3.05▼$3.1950-Day Range$2.16▼$3.4852-Week Range$1.77▼$4.05Volume1,663 shsAverage Volume6,677 shsMarket Capitalization$78.30 millionP/E RatioN/ADividend YieldN/APrice Target$6.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Anebulo Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside118.2% Upside$6.67 Price TargetShort InterestHealthy0.48% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.43Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.02 out of 5 starsMedical Sector601st out of 970 stocksPharmaceutical Preparations Industry286th out of 449 stocks 3.5 Analyst's Opinion Consensus RatingAnebulo Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.67, Anebulo Pharmaceuticals has a forecasted upside of 118.2% from its current price of $3.06.Amount of Analyst CoverageAnebulo Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.48% of the float of Anebulo Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAnebulo Pharmaceuticals has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Anebulo Pharmaceuticals has recently increased by 1,444.44%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAnebulo Pharmaceuticals does not currently pay a dividend.Dividend GrowthAnebulo Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANEB. Previous Next 3.0 News and Social Media Coverage News SentimentAnebulo Pharmaceuticals has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Anebulo Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest5 people have searched for ANEB on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Anebulo Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anebulo Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders85.70% of the stock of Anebulo Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 27.44% of the stock of Anebulo Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Anebulo Pharmaceuticals is -6.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anebulo Pharmaceuticals is -6.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnebulo Pharmaceuticals has a P/B Ratio of 4.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Anebulo Pharmaceuticals (NASDAQ:ANEB) StockAnebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. The company was incorporated in 2020 and is based in Lakeway, Texas.Read More ANEB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANEB Stock News HeadlinesSeptember 28, 2023 | americanbankingnews.comAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) to Post Q3 2024 Earnings of ($0.11) Per Share, HC Wainwright ForecastsSeptember 26, 2023 | americanbankingnews.comAnebulo Pharmaceuticals (NASDAQ:ANEB) Receives Buy Rating from HC WainwrightSeptember 30, 2023 | Weiss Ratings (Ad)Overlooked AI Stock Gets Urgent "Buy"We issued our first "Buy" rating on Apple when it traded at the equivalent of 56 cents per share. It's up 32,571% since. And while Nvidia is up 3x this year… We called it back in 2011. And it has surged 97x (9,624% to be exact) since then. Now, our Weiss Ratings has issued a "Buy" on a stock that's leading the AI revolution in one of the most profitable industries.September 25, 2023 | msn.comHC Wainwright & Co. Reiterates Anebulo Pharmaceuticals (ANEB) Buy RecommendationSeptember 25, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Anebulo Pharmaceuticals (ANEB)September 23, 2023 | nasdaq.comMaxim Group Initiates Coverage of Anebulo Pharmaceuticals (ANEB) with Buy RecommendationSeptember 23, 2023 | americanbankingnews.comAnebulo Pharmaceuticals (NASDAQ:ANEB) Coverage Initiated by Analysts at Maxim GroupSeptember 22, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Aurinia Pharmaceuticals (AUPH) and Aquestive Therapeutics (AQST)September 30, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.September 21, 2023 | americanbankingnews.comBrokers Set Expectations for Anebulo Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:ANEB)September 20, 2023 | finance.yahoo.comAnebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent UpdatesSeptember 18, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Anebulo Pharmaceuticals (ANEB) with Buy RecommendationSeptember 18, 2023 | markets.businessinsider.comSubstance Use Disorder Focused Anebulo Could Be Attractive Acquisition Target, Analyst SaysSeptember 18, 2023 | markets.businessinsider.comAnebulo Pharmaceuticals (ANEB) Has a New Rating from H.C. WainwrightAugust 30, 2023 | finance.yahoo.comAnebulo Pharmaceuticals to Present at Upcoming Investor and Scientific ConferencesAugust 22, 2023 | finance.yahoo.comAnebulo (ANEB) Gains on Positive FDA Response for ANEB-001August 21, 2023 | markets.businessinsider.comAnebulo Pharma: FDA Provides Favorable Input On Studies To Support ANEB-001 ApprovalAugust 21, 2023 | finance.yahoo.comAnebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 ExtensionMay 30, 2023 | finance.yahoo.comWe Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Needs To Drive Business Growth CarefullyMay 19, 2023 | finance.yahoo.comDown -26.43% in 4 Weeks, Here's Why You Should You Buy the Dip in Anebulo Pharmaceuticals, Inc. (ANEB)May 18, 2023 | msn.comBenchmark Reiterates Anebulo Pharmaceuticals (ANEB) Speculative Buy RecommendationMay 11, 2023 | finanznachrichten.deAnebulo Pharmaceuticals, Inc.: Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent UpdatesMay 11, 2023 | msn.comAnebulo Pharmaceuticals: Q3 Earnings InsightsMay 11, 2023 | finance.yahoo.comAnebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent UpdatesMarch 29, 2023 | msn.comAntidote For THC? Anebulo Releases Positive Clinical Data Showing Potential Of Its Drug For Treatment Of Acute Cannabinoid IntoxicationMarch 28, 2023 | finance.yahoo.comAnebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid IntoxicationMarch 8, 2023 | finance.yahoo.comAnebulo Pharmaceuticals Expands its Integrated and Outsourced SolutionsSee More Headlines Receive ANEB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anebulo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ANEB Company Calendar Last Earnings11/12/2021Today9/30/2023Next Earnings (Estimated)11/09/2023Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ANEB CUSIPN/A CIK1815974 Webwww.anebulo.com Phone512-598-0931FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.67 High Stock Price Forecast$8.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+118.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,730,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-80.67% Return on Assets-74.72% Debt Debt-to-Equity RatioN/A Current Ratio10.92 Quick Ratio9.68 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.65 per share Price / Book4.70Miscellaneous Outstanding Shares25,630,000Free Float3,666,000Market Cap$78.30 million OptionableNot Optionable Beta-1.39 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Joseph F. Lawler M.D. (Age 51)Ph.D., Founder & Chairman Comp: $11kMr. Simon J. Allen B.Sc. (Age 55)M.B.A., MBA, CEO & Director Comp: $450kDr. Kenneth C. Cundy Ph.D. (Age 64)Chief Scientific Officer Comp: $345.53kMs. Sandra A. Gardiner (Age 57)Acting Chief Financial Officer Mr. Scott L. AndersonHead of Investor Relations & Public AffairsKey CompetitorsKezar Life SciencesNASDAQ:KZRBioXcel TherapeuticsNASDAQ:BTAIEvelo BiosciencesNASDAQ:EVLOSyros PharmaceuticalsNASDAQ:SYRSNkartaNASDAQ:NKTXView All Competitors ANEB Stock - Frequently Asked Questions Should I buy or sell Anebulo Pharmaceuticals stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anebulo Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANEB shares. View ANEB analyst ratings or view top-rated stocks. What is Anebulo Pharmaceuticals' stock price forecast for 2023? 3 Wall Street research analysts have issued twelve-month price targets for Anebulo Pharmaceuticals' stock. Their ANEB share price forecasts range from $6.00 to $8.00. On average, they anticipate the company's share price to reach $6.67 in the next twelve months. This suggests a possible upside of 118.2% from the stock's current price. View analysts price targets for ANEB or view top-rated stocks among Wall Street analysts. How have ANEB shares performed in 2023? Anebulo Pharmaceuticals' stock was trading at $2.4237 at the start of the year. Since then, ANEB shares have increased by 26.0% and is now trading at $3.0550. View the best growth stocks for 2023 here. Are investors shorting Anebulo Pharmaceuticals? Anebulo Pharmaceuticals saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 13,900 shares, an increase of 1,444.4% from the August 31st total of 900 shares. Based on an average trading volume of 6,300 shares, the days-to-cover ratio is presently 2.2 days. Currently, 0.5% of the company's stock are sold short. View Anebulo Pharmaceuticals' Short Interest. When is Anebulo Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our ANEB earnings forecast. How were Anebulo Pharmaceuticals' earnings last quarter? Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) issued its quarterly earnings data on Friday, November, 12th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04. When did Anebulo Pharmaceuticals IPO? (ANEB) raised $21 million in an initial public offering (IPO) on Friday, May 7th 2021. The company issued 3,000,000 shares at a price of $6.00-$8.00 per share. The Benchmark Company acted as the underwriter for the IPO. What is Anebulo Pharmaceuticals' stock symbol? Anebulo Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANEB." How do I buy shares of Anebulo Pharmaceuticals? Shares of ANEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Anebulo Pharmaceuticals' stock price today? One share of ANEB stock can currently be purchased for approximately $3.06. How much money does Anebulo Pharmaceuticals make? Anebulo Pharmaceuticals (NASDAQ:ANEB) has a market capitalization of $78.30 million. The company earns $-11,730,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. How can I contact Anebulo Pharmaceuticals? The official website for the company is www.anebulo.com. The company can be reached via phone at 512-598-0931 or via email at ybriggs@lhai.com. This page (NASDAQ:ANEB) was last updated on 9/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anebulo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.